2025 annual financial data
Anika Therapeutics 2025 Operating margin
Direct answer
Operating margin was -9.8%.
Operating income was -11,051,000 USD and net income was -10,880,000 USD.
Operating cash flow was 11,188,000 USD.
Get free Anika Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 112,819,000 USD
- Operating income
- -11,051,000 USD
- Net income
- -10,880,000 USD
- Operating cash flow
- 11,188,000 USD